Innovent Biologics and HUTCHMED Announce Priority Review for Novel Combination Therapy in Advanced Endometrial Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

April 02, 2024 | Tuesday | News
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

Incyte and China Medical System Holdings Limited  are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology m...

April 02, 2024 | Tuesday | News
China Medical University Hospital (CMUH) Innovates iDREAM for Home Detection of Sleep Apnea

Snoring can be an alarming sign of obstructive sleep apnea syndrome (OSAS). Studies showed that 50% of individuals who snore may experience sleep apnea, wh...

April 01, 2024 | Monday | News
HUTCHMED's Savolitinib Advances for Expanded Approval in China, Promising New Hope for Lung Cancer Patients

  — If approved, would confirm 2021 conditional approval and expand indication to more patients — HUTCHMED (China) Lim...

March 28, 2024 | Thursday | News
Biocytogen Partners with ABL Bio to Forge Ahead in Bispecific Antibody-Active Ingredient Conjugate Development

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company focused on the development of novel antibody the...

March 26, 2024 | Tuesday | News
Biotech Lobbying Powerhouse BIO Ends Association with WuXi AppTec Amid Security Crackdown

Biotechnology Innovation Organization (BIO), a leading lobbying group in Washington, D.C., announced its decision to sever ties with WuXi AppTec, a Chinese...

March 15, 2024 | Friday | Reports
Fujifilm Owen Technology Products Approved, Expanding Reproductive Tech in China

Fujifilm Irvin Technology is a leader in the innovation and manufacturing of cell culture solutions in the global life sciences and medical markets. With t...

February 27, 2024 | Tuesday | News
Bitterroot Bio and Biotheus Launch Joint Effort to Create Bispecific Proteins for Cardio-Immunology

Bitterroot Bio, a leader in innovative treatments for cardiovascular diseases, and Biotheus, a pioneer in monoclonal and multi-specific antibody design, an...

February 27, 2024 | Tuesday | News
Biocytogen Pharmaceuticals Announces Antibody Evaluation and Option Agreement with Gilead Sciences

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315)  announces an antibody evaluation and option agreement with Gil...

February 20, 2024 | Tuesday | News
HUTCHMED & Inmagene Advance, License Drug Candidates IMG-007 and IMG-004

Following the exercise of the Options and subject to receipt by HUTCHMED of ordinary shares representing approximately 7.5% of shares (fully diluted) in In...

February 02, 2024 | Friday | News
MGI Expands Automation Product Lines for Life Science Research

MGI Tech Co., Ltd. (referred to as MGI), a leading provider of cutting-edge tools and technology for life science and healthcare research, today announced ...

January 30, 2024 | Tuesday | News
HUTCHMED Granted ELUNATE® Approval in Hong Kong for Metastatic Colorectal Cancer Treatment

— First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong Kong&...

January 30, 2024 | Tuesday | News
InnoCare Initiates Clinical Trial for Zurletrectinib in China, Administering First Dose to Pediatric Patient

Zurletrectinib, developed by InnoCare, is a pan-TRK inhibitor which markedly inhibits the activity of the wild type TRKA, TRKB and TRKC, as well as mutant ...

January 24, 2024 | Wednesday | News
Biocytogen debuts RenBiologics, a sub-brand specializing in out-licensing fully human antibodies for therapeutic development

Biocytogen’s fully human antibody sequences were generated by proprietary RenMice strains, each engineered to lack a certain drug target gene. From M...

January 24, 2024 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close